AD Neuroprotective Peptide and Peptide-Based Therapy Companies

Overview

Overview

Neuroprotective peptides and peptide-based therapies represent a promising class of disease-modifying approaches for Alzheimer's disease (AD). These short amino acid sequences (typically 5-40 residues) are derived from endogenous neuropeptides or engineered synthetically to protect neurons from amyloid toxicity, oxidative stress, excitotoxicity, and neuroinflammation["@craik2013"].

Unlike small molecule drugs, peptides can interact with larger surface areas on target proteins, enabling more specific modulation of protein-protein interactions that are difficult to target with traditional pharmaceuticals. The therapeutic rationale for neuroprotective peptides in AD rests on several key observations: peptides can cross the blood-brain barrier with appropriate modifications; they target multiple pathways involved in neurodegeneration simultaneously; and several have demonstrated favorable safety profiles in clinical trials["@Brimson2019"].

This category page consolidates companies developing neuroprotective peptide therapeutics for AD, including:

• Peptide fragments derived from endogenous proteins
• Synthetic peptide analogs designed to enhance neuroprotection
• Peptide-based approaches targeting amyloid-beta toxicity
• Synaptic protection peptides
• Brain-derived neurotrophic factor (BDNF) mimetics

Key Companies and Programs

Neurotrope Bioscience (Acumen Pharmaceuticals)

Neurotrope Bioscience (acquired by Acumen Pharmaceuticals) focused on developing bryostatin-based therapeutics for Alzheimer's disease. The company's lead candidate, bryostatin-1 (also known as Altumab or NRO-1), is a protein kinase C (PKC) activator that promotes synaptic plasticity and neurotrophic factor expression.

• Focus: Neurotrophic factor delivery and synaptic plasticity
• Lead Candidate: Bryostatin-1
• Mechanism: PKC activation promotes synaptogenesis, enhances long-term potentiation (LTP), and protects against excitotoxicity. Bryostatin has been shown to increase synaptic protein expression, including synapsin I and PSD-95, in preclinical models
• Stage: Phase 2 completed
• ClinicalTrials.gov: NCT04594060
• Related Page: [Acumen Pharmaceuticals](/companies/acumen-pharmaceuticals)

Cognition Therapeutics

Cognition Therapeutics is focused on developing small molecule therapeutics targeting sigma-2 receptors to treat Alzheimer's disease and other protein aggregation disorders. The company's lead candidate, CT-1812 (ELND005), is a novel sigma-2 receptor modulator that has progressed through Phase 1 and Phase 2 clinical trials.

• Focus: Synaptic protection and function restoration
• Lead Candidate: CT-1812 (sigma-2 receptor modulator)
• Mechanism: CT-1812 targets the sigma-2 receptor complex, which is involved in cellular stress response and cholesterol homeostasis. The compound displaces toxic oligomers from synaptic membranes, thereby protecting synaptic integrity and function
• Stage: Phase 1-2 completed
• ClinicalTrials.gov: NCT05531695

Spinogenix

Spinogenix is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting synaptic regeneration in Alzheimer's disease and other neurodegenerative conditions.

• Focus: Synaptic repair and cognitive restoration
• Lead Candidate: SPG-302
• Mechanism: Promotes synaptogenesis and dendritic spine formation through novel mechanisms
• Stage: Phase 1 ongoing
• Related Page: [Spinogenix](/companies/spinogenix)

Prothelia

Prothelia is focused on developing protein replacement therapies and neuroprotective molecules for neurodegenerative diseases.

• Focus: Protein replacement and neuroprotection
• Mechanism: Development of neurotrophic factor mimetics
• Stage: Preclinical/IND-enabling

Alector

Alector is developing immune-neurology therapeutics that harness the brain's immune system to treat neurodegenerative diseases. While primarily focused on TREM2 and other immune targets, their approach includes neuroprotective mechanisms.

• Focus: Immune-mediated neuroprotection
• Lead Candidates: AL001, AL002 (TREM2 agonists)
• Stage: Phase 2/3

Neuraly (Formerly vTv Therapeutics)

Neuraly is a clinical-stage biopharmaceutical company exclusively focused on developing GLP-1 receptor agonists for neurodegenerative diseases, including peptide-based approaches.

• Focus: GLP-1 based neuroprotection
• Lead Candidate: NLY01
• Stage: Phase 1-2
• Related Page: [Neuraly](/companies/neuraly)

Peptide Classes in Development

BDNF-Derived Peptides

Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin that supports neuronal survival, synaptic plasticity, and cognitive function. BDNF and its derivatives have been extensively studied for neuroprotective applications:

| Company | Peptide | Target | Stage |
|---------|---------|--------|-------|
| Various | BDNF 1-28 | TrkB agonist | Preclinical |
| Various | BDNF loop 1 peptide | TrkB agonist | Preclinical |
| Neurotrope | Bryostatin-1 | PKC activator | Phase 2 |

NAP (NAPVSIPQ) Peptides

NAP (NAPVSIPQ) is an 8-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). It binds to tubulin and promotes microtubule stabilization.

| Company | Product | Stage |
|---------|---------|-------|
| Formerly Allon Therapeutics | Davunetide (AL-108) | Phase 2 |

Anti-Amyloid Peptides

Peptides designed to prevent or disrupt amyloid-beta aggregation:

| Company | Product | Mechanism | Stage |
|---------|---------|-----------|-------|
| Various | Aβ aggregation inhibitors | Beta-sheet blockers | Preclinical |

Sigma-2 Receptor Modulators

Small molecule/peptide modulators that protect synapses from toxic oligomers:

| Company | Product | Mechanism | Stage |
|---------|---------|-----------|-------|
| Cognition Therapeutics | CT-1812 | Sigma-2 modulation | Phase 2 |

Pipeline Overview

| Company | Lead Program | Mechanism | Indication | Stage |
|---------|---------------|-----------|------------|-------|
| Acumen/NBC | Bryostatin | PKC activation | AD | Phase 2 |
| Cognition Therapeutics | CT-1812 | Sigma-2 | AD | Phase 2 |
| Spinogenix | SPG-302 | Synaptogenesis | AD | Phase 1 |
| Neuraly | NLY01 | GLP-1 | AD/PD | Phase 1-2 |
| Alector | AL001/002 | TREM2 | AD | Phase 2/3 |

Related Pages

• [Neuroprotective Peptides](/therapeutics/neuroprotective-peptides)](/therapeutics)
• [Peptide-Based Therapeutics](/therapeutics/peptide-therapeutics-neurodegeneration)](/therapeutics)
• [AD Synaptic Repair and Neuroprotection Companies](/companies/ad-synaptic-repair-neuroprotection-companies)
• [AD Neurotrophin and Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
• [Anti-Amyloid Therapeutics](/therapeutics/anti-amyloid-therapeutics)

References